Cempra Pharmaceuticals has announced that intravenous solithromycin demonstrated tolerability and a favourable pharmacokinetic profile in a Phase I study.
The single-centre, randomised, double-blind and placebo-controlled dose-escalation study enrolled 42 patients.
The results showed that solitromycin demonstrated a favourable pharmacokinetic profile in single doses up to 800mg, and achieved plasma concentrations of about four mg/mL
The drug, the first macrolide to offer both oral and intravenous forms of administration, has proven to be potent against respiratory pathogens.
Cempra Pharmaceuticals clinical research vice-president, David Oldach, said solithromycin is currently in a Phase II clinical trial for serious community-acquired bacterial pneumonia.